Kamada Secures FDA Approval for New In-House Rabies Testing Lab
KMDA sits 22% above its 52-week low of $6.5.
Summary
Kamada announced FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory, enhancing operational efficiencies and quality control for its leading KEDRAB and KAMRAB products.
Key Events · Product Development and Regulatory · KMDA
-
FDA Approval for Rabies Testing Lab
Kamada received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, located at its Beit Kama plant in Israel. This lab performs the gold standard test for rabies-neutralizing antibodies.
-
Enhanced Operational Efficiency
The new laboratory is expected to increase operational efficiencies and strengthen quality control for the manufacturing of KEDRAB® and KAMRAB®, which together generated over $70 million in sales in 2025.
-
Strengthened Quality Infrastructure
This approval expands Kamada's advanced testing capabilities and reinforces its position as a vertically integrated specialty plasma-derived company, reducing reliance on external testing.
Analysis · KMDA · Life Sciences
This FDA approval for Kamada's in-house rabies testing laboratory is important because it enhances the company's vertical integration and quality control capabilities for its leading KEDRAB and KAMRAB products. By bringing critical testing in-house, Kamada expects to achieve increased operational efficiencies, which can positively impact the profitability and reliability of a franchise that generated over $70 million in sales last year.
At the time of this filing, KMDA was trading at $7.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $450.5M. The 52-week trading range was $6.50 to $9.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.